주요 콘텐츠로 건너뛰기

귀하의 브라우저가 완벽하게 지원되지 않습니다. 옵션이 있는 경우 최신 버전으로 업그레이드하거나 Mozilla Firefox, Microsoft Edge, Google Chrome 또는 Safari 14 이상을 사용하세요. 가능하지 않거나 지원이 필요한 경우 피드백을 보내주세요.

이 새로운 경험에 대한 귀하의 의견에 감사드립니다.의견을 말씀해 주세요 새 탭/창에서 열기

Elsevier
엘스비어와 함께 출판

Profile

Twan Lammers

TL

Twan Lammers

Talk Title: Strategies to Promote Cancer Nanomedicine Clinical Translation

University of Aachen (RWTH), Germany

Twan Lammers obtained a D.Sc. in Radiation Oncology from Heidelberg University in 2008 and a Ph.D. in Pharmaceutical Technology from Utrecht University in 2009. In the same year, he started the Nanomedicine and Theranostics group at RWTH Aachen University. In 2014, he was promoted to full professor of medicine at RWTH Aachen University Clinic. His group aims to individualize and improve disease treatment by combining drug targeting with imaging. To this end, image-guided (theranostic) drug delivery systems are being developed, as well as materials and methods to monitor tumor growth, angiogenesis, inflammation, fibrosis and metastasis. He has received multiple scholarships and awards, including ERC starting, consolidator and proof-of-concept grants, the CRS Young Investigator Award, the Adritelf International Award, the Belgian Society for Pharmaceutical Sciences International Award, and the JNB Trailblazer Award. He served as the president of the Controlled Release Society in 2023-2024, and he has been a council member of the European Society for Molecular Imaging for almost 10 years. He is a member of the editorial board of 10 journals, and acts as associate editor for JCR, DDTR and MIB. Since 2019, he is included in the Clarivate Analytics list of Highly Cited Researchers.

Recent Publications:

1. Bhatia S, Chen X, Dobrovolskaia M, Lammers T. Cancer nanomedicine. Nat Rev Cancer 22, 550-556 (2022)

2. Biancacci I, De Lorenzi F, Theek B, Bai X, May J, Consolino L, Baues M, Moeckel D, Gremse F, Stillfried S, El Shafei A, Benderski K, Shalmani A, Wang A, Momoh J, Pena Q, Buhl E, Buyel J, Hennink W, Kiessling F, Metselaar J, Shi Y, Lammers T. Monitoring EPR effect dynamics during nanotaxane treatment with theranostic polymeric micelles. Adv Sci e2103745 (2022)

3. Miedema I, Zwezerijnen G, Huisman M, Doeleman E, Mathijssen R, Lammers T, Hu Q, van Dongen G, Rijcken C, Vugts D, Menke C. PET‐CT Imaging of polymeric nanoparticle tumor accumulation in patients. Adv Mater 34: 2201043 (2022)

4. Dasgupta A, Sun T, Palomba R, Rama E, Zhang Y, Power C, Liu M, Sarode A, Weiler M, Motta A, Porte C, Magnuska Z, Elshafei A, Barmin R, Graham A, McClelland A, Rommel D, Stickeler E, Kiessling F, Pallares R, De Laporte L, Decuzzi P, McDannold N, Mitragotri S, Lammers T. Non-spherical ultrasound microbubbles. PNAS 120, e2218847120 (2023)

5. Dasgupta A, Sun T, Rama E, Motta A, Zhang Y, Power C, Moeckel D, Moosavifar M, Barmin R, Porte C, Buhl E, Bastard C, Pallares R, Kiessling F, McDannold N, Mitragotri S, Lammers T. Transferrin receptor-targeted nonspherical microbubbles for blood-brain barrier sonopermeation. Adv Mater 35, e2308150 (2023)

6. Sofias A, Lammers T. Multidrug nanomedicine. Nat Nanotechnol 18, 104-106 (2023)

7. Lammers T. Nanomedicine tumor targeting. Adv Mater 36: e2312169 (2024)

8. Dasgupta A, Sofias A, Kiessling F, Lammers T. Nanoparticle delivery to tumors: From EPR and ATR mechanisms to clinical impact. Nat Rev Bioeng 2: 714-716 (2024)

9. May J, Moss J, Mueller F, Golombek S, Biancacci I, Rizzo L, Gremse F, Pola R, Pechar M, Etrych T, Becker S, Trautwein C, Buelow R, Boor P, Knuechel R, Stilfried S, Storm G, Puri S, Barry S, Schulz V, Kiessling F, Ashford M, Lammers T. Histopathological biomarkers for predicting the tumour accumulation of nanomedicines. Nat Biomed Eng 8, 1366-1378 (2024)

10. Benderski K, Lammers T, Sofias A. Analysis of multidrug cancer nanomedicine. Nat Nanotechnol (in press)